▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Immunic (NASDAQ: IMUX)

$0.95

(0.5%)

$0.01

Price as of August 22, 2025, 4:00 p.m. ET

Immunic Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
IMUX	-37.50%	-94.85%	-44.71%	-96%
S&P	+16.09%	+90.36%	+13.72%	+123%

Immunic Company Info

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.

News & Analysis

Featured Article

Immunic (IMUX) Q2 Loss Widens 25%

Motley Fool Markets Team | Aug 7, 2025

Featured Article

Why Immunic Plummeted by 21% on Thursday

Word of a new share issue made investors feel queasy.

Eric Volkman | Jul 15, 2021

Why Immunic Stock Is Soaring Today

Prosper Junior Bakiny | Aug 26, 2020

An analyst says buy.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services